Drug Information

Drug General Information
Drug ID
D0B5HF
Former ID
DNCL002837
Drug Name
BI-135585
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [523331]
Company
Boehringer Ingelheim Pharmaceuticals
Target and Pathway
Target(s) Corticosteroid 11-beta-dehydrogenase, isozyme 1 Target Info Modulator [551800]
KEGG Pathway Steroid hormone biosynthesis
Metabolism of xenobiotics by cytochrome P450
Metabolic pathways
Chemical carcinogenesis
NetPath Pathway IL1 Signaling Pathway
FSH Signaling Pathway
PathWhiz Pathway Steroidogenesis
Reactome Glucocorticoid biosynthesis
WikiPathways Prostaglandin Synthesis and Regulation
Metabolism of steroid hormones and vitamin D
Glucocorticoid & Mineralcorticoid Metabolism
References
Ref 523331ClinicalTrials.gov (NCT01282970) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes. U.S. National Institutes of Health.
Ref 551800New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.